David Mayers has been named President of WellSpring Pharma Services. He brings 25 years of pharmaceutical manufacturing experience, most recently serving as Vice President Manufacturing Operations at Purdue Pharma. Mr. Mayers will join the senior leadership team and will assume immediate responsibility for all activities associated with the Pharma Services business unit, overseeing Plant Operations, Business Development and Quality & Regulatory Affairs.
“We are excited with the addition of David to the WellSpring Pharma Services team.” said Wendy Shusko, President of WellSpring Pharmaceutical Corporation. “The increasing complexity of the pharmaceutical environment, coupled with our desire to ensure continued growth and the appropriate positioning of WellSpring Pharma Services has necessitated recent decisions with this senior level role. David will provide the strategic and operational leadership to ensure the transformation and growth strategy of the Canadian operations, including creating a continuous improvement culture and optimizing organizational capability, allowing the organization to maximize growth opportunities and overall profitability.”
Mr. Mayers earned his MBA from the University of Toronto, his Hons. BSc. from the University of Guelph and has held many diverse leadership positions in Manufacturing, Quality, Research & Development, Supply Chain, Operations, Project Management and Strategy. Over the last 11 years at Purdue, he has directly overseen the expansion of the facility, implemented a Lean environment and facilitated a corporate QMS supporting global regulatory readiness of the Canadian facility; carving out a significant export and third party manufacturing presence. David is known for his ability to provide strategic focus and leadership through times of growth and change.
WellSpring Pharma Services, a Founding Member of the Pharma & Biopharma Outsourcing Association, is a provider of full-service pharmaceutical contract manufacturing and packaging services for virtually all solid and semisolid dosage form products including tablets, capsules, creams, lotions, ointments, gels and oral liquids. Its facility is cGMP compliant and has been successfully inspected by Health Canada and the U.S. Food and Drug Administration.